Publications by authors named "Kari Remes"

Claim this Profile
R
Reduced Intensity transplantation vs chemotherapy in CR1. A prospective, pseudorandomized study in 50-70 year old AML patients.
Mats Brune, Thomas Kiss, Harald Anderson, Malin Nicklasson, Robert Delage, Kari Remes

Bone Marrow Transplant· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group.
Lene Kongsgaard Nielsen, Fredrik Schjesvold, Sören Möller, Nina Guldbrandsen, Markus Hansson, Kari Remes

J Patient Rep Outcomes· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.
Henrik Gregersen, Valdas Peceliunas, Kari Remes, Fredrik Schjesvold, Niels Abildgaard

Eur J Haematol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide.
Barbara Gamberi, Christian Berthou, Miguel Hernandez, Gianpietro Semenzato, Eleni Tholouli, Kari Remes

Clin Lymphoma Myeloma Leuk· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013.
Kari Remes, Pekka Anttila, Raija Silvennoinen, Mervi Putkonen, Hanna Ollikainen

PLoS One· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contactless online characterization of large-area conductive thin films by thermography and induction.
Kari Remes, Antti Järvenpää, Tapio Fabritius

Opt Lett· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe neutropenia after rituximab-treatment of multiple sclerosis.
Eero Rissanen, Kari Remes, Laura Airas

Mult Scler Relat Disord· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of adult acute myeloid leukemia.
Joni Järvenpää, Maija Itälä-Remes, Tommi Kauko, Urpu Salmenniemi, Marjut Kauppila, Kari Remes

Duodecim· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thermography based online characterization of conductive thin films in large-scale electronics fabrication.
Kari Remes, Kimmo Leppänen, Tapio Fabritius

Opt Express· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.
Johan Törlén, Olle Ringdén, Karin Garming-Legert, Per Ljungman, Jacek Winiarski, Kari Remes, Maija Itälä-Remes

Haematologica· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost analysis of a randomized stem cell mobilization study in multiple myeloma.
Ville Varmavuo, Raija Silvennoinen, Pekka Anttila, Marjaana Säily, Marja Sankelo, Kari Remes

Ann Hematol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Prophylactic platelet transfusions].
Minna Ilmakunnas, Kari Remes, Seppo Hiippala, Heikki Mäkisalo, Fredrik Åberg

Duodecim· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.
Jaakko Valtola, Raija Silvennoinen, Antti Ropponen, Timo Siitonen, Marjaana Säily, Kari Remes

Transfusion· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Hemolysis and metastatic cancer in an elderly man].
Kari Remes, Merja Raade, Lauri Karhumäki, Tuomo Timonen, Matti J Välimäki

Duodecim· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Henrik Hjorth-Hansen, Leif Stenke, Stina Söderlund, Arta Dreimane, Hans Ehrencrona, Kari Remes

Eur J Haematol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
Perttu Koskenvesa, Anna Kreutzman, Peter Rohon, Markus Pihlman, Emmi Vakkila, Kari Remes

Eur J Haematol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Adult acute lymphoblastic leukemia - 20-year treatment results at TYKS].
Rami Nylund, Maija Itälä-Remes, Tommi Kauko, Marjut Kauppila, Mervi Putkonen, Kari Remes

Duodecim· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study.
Tapani Ruutu, Eeva Juvonen, Mats Remberger, Kari Remes, Liisa Volin

Biol Blood Marrow Transplant· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of pretransplant iron overload measured with magnetic resonance imaging on severe infections in allogeneic stem cell transplantation.
Johanna M Virtanen, Maija A Itälä-Remes, Kari J Remes, Tero Vahlberg, Jani P Saunavaara

Eur J Haematol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.
Ulf-Henrik Mellqvist, Peter Gimsing, Oyvind Hjertner, Stig Lenhoff, Edward Laane, Kari Remes

Blood· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients.
Raija Silvennoinen, Veli Kairisto, Tarja-Terttu Pelliniemi, Mervi Putkonen, Pekka Anttila, Kari Remes

Br J Haematol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation.
Kate Cwynarski, Anja van Biezen, Liesbeth de Wreede, Stephan Stilgenbauer, Donald Bunjes, Kari Remes

J Clin Oncol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma.
Urpu Salmenniemi, Kari Remes

Hematol Rep· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Stem cell transplantation in myelofibrosis].
Aura Toivari, Maija Itälä-Remes, Marjut Kauppila, Mervi Putkonen, Urpu Salmenniemi, Kari Remes

Duodecim· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
Bengt Simonsson, Tobias Gedde-Dahl, Berit Markevärn, Kari Remes, Jesper Stentoft

Blood· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis